Cargando…
Syndecan-2 regulates PAD2 to exert antifibrotic effects on RA-ILD fibroblasts
Rheumatoid arthritis (RA)-associated interstitial lung disease (RA-ILD) is the most common pulmonary complication of RA, increasing morbidity and mortality. Anti-citrullinated protein antibodies have been associated with the development and progression of both RA and fibrotic lung disease; however,...
Autores principales: | Tsoyi, Konstantin, Esposito, Anthony J., Sun, Bo, Bowen, Ryan G., Xiong, Kevin, Poli, Fernando, Cardenas, Rafael, Chu, Sarah G., Liang, Xiaoliang, Ryter, Stefan W., Beeton, Christine, Doyle, Tracy J., Robertson, Matthew J., Celada, Lindsay J., Romero, Freddy, El-Chemaly, Souheil Y., Perrella, Mark A., Ho, I.-Cheng, Rosas, Ivan O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857282/ https://www.ncbi.nlm.nih.gov/pubmed/35181688 http://dx.doi.org/10.1038/s41598-022-06678-7 |
Ejemplares similares
-
The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD
por: Kolb, Martin, et al.
Publicado: (2022) -
Mesenchymal stromal cell‐derived syndecan‐2 regulates the immune response during sepsis to foster bacterial clearance and resolution of inflammation
por: Han, Junwen, et al.
Publicado: (2021) -
Are genes the missing link to detect and prognosticate RA-ILD?
por: Vermant, Marie, et al.
Publicado: (2023) -
Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD
por: Shumar, John N., et al.
Publicado: (2021) -
Smoking and Subclinical ILD in RA versus the Multi-Ethnic Study of Atherosclerosis
por: Johnson, Cheilonda, et al.
Publicado: (2016)